

Supplementary Materials:

Table S1: Secondary outcomes of included studies

Auth or(s)	ITM Group					Control					N/V prophylaxi s	N/V treatment
	Nau sea (%)	Vom iting (%)	Prur itus (%)	Urin ary Rete ntion (%)	Respir atory Depre ssion (%)	Nau sea (%)	Vom iting (%)	Prur itus (%)	Urin ary Rete ntion (%)	Respir atory Depre ssion (%)		
Segal et al., 2013 [32]	NR	NR	38 (n = 7)	NR	NR	NR	NR	0	NR	NR	4mg ondansetro n	-
Bae et al., 2017 [27]	40 (n = 6)	20 (n = 3)	60 (n = 9)	NR	0	40 (n = 6)	6 (n = 1)	14 (n = 2)	NR	0	-	10mg metoclopra mide
Koni ng et al., 2020 [9]	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	0.625mg IV dehydrobe nzperidol + 4mg IV ondansetro n	0.625mg IV dehydrobe nzperidol
Shim #1 et al., 2020 [33]	30 (n = 9)	6.7 (n = 2)	16.7 (n = 5)	NR	NR	6.7 (n = 2)	0	0	NR	NR	0.0025mg/h basal infusion ramosetron	-
Dha wan et al., 2021 [29]	36.4 (n = 12)	0	21.2 (n = 7)	0	0	8.1 (n = 3)	0	5.4 (n = 2)	2.7 (n = 1)	0	-	Ondansetro n
Shim #2 et al., 2021 [34]	24 (n = 6)	4 (n = 1)	16 (n = 4)	NR	0	8 (n = 2)	0	0	NR	0	0.0025mg/h basal infusion ramosetron	-
Chae et al., 2022 [28]	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	-	-
Russ o et al., 2022 [31]	Recovery room: 18 (n = 2) 1H: 18 (n = 2) 12H: 9 (n = 1) 24H: 9 (n = 1)					TI group Recovery room: 0 1H = 18 (n = 2) 12H = 27 (n = 3) 24H = 27 (n = 3)					-	8mg ondansetro n

TAP Block											
group											
Recovery											
room: 9											
(n = 1)											
1H: 18 (n = 2)											
12H: 18 (n =											
2)											
24H: 0											
Engst											
röm											
et al.,											
2023											
[30]											
NR	NR	NR	6.52	0	NR	NR	NR	4.17	NR	Betamethas	-
			(n = 3)					(n = 2)		one +	
										ondansetro	
										n	

Legend: NR not reported, TAP Transversus Abdominal Plane, TI Tramadol Infusion. Continuous data are presented as absolute values unless otherwise stated.

Figure S1: Sensitivity analysis after exclusion studies not including basic analgesics in both groups.




Figure S2: Funnel plot for publication bias in included studies.

